LAVA Therapeutics (NASDAQ:LVTX) Receives Market Outperform Rating from JMP Securities

JMP Securities reissued their market outperform rating on shares of LAVA Therapeutics (NASDAQ:LVTX) in a report published on Wednesday morning, Benzinga reports. They currently have a $6.00 price objective on the stock.

Separately, HC Wainwright reissued a buy rating and set a $6.00 target price on shares of LAVA Therapeutics in a research note on Friday, June 28th.

LAVA Therapeutics Trading Up 1.1 %

NASDAQ LVTX opened at $1.89 on Wednesday. LAVA Therapeutics has a one year low of $1.13 and a one year high of $6.47. The company has a 50-day simple moving average of $1.92 and a 200-day simple moving average of $2.40. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.42 and a current ratio of 7.42. The firm has a market capitalization of $47.91 million, a PE ratio of -1.75 and a beta of 0.54.

LAVA Therapeutics (NASDAQ:LVTX) last posted its earnings results on Tuesday, August 20th. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative return on equity of 51.90%. On average, equities analysts forecast that LAVA Therapeutics will post -1.27 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in LAVA Therapeutics stock. Pathway Financial Advisors LLC lifted its stake in LAVA Therapeutics (NASDAQ:LVTX) by 328.6% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 60,000 shares of the company’s stock after acquiring an additional 46,000 shares during the period. Pathway Financial Advisors LLC’s holdings in LAVA Therapeutics were worth $108,000 as of its most recent filing with the Securities and Exchange Commission.

LAVA Therapeutics Company Profile

LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.